Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

ignificant improvement in skin lesions including facial angiofibromas was observed, which can be a key concern for people living with TSC."  

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(8). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes(9). When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism(2,9). By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation and blood vessel growth related to angiomyolipoma associated with TSC(2,8,9).

"The positive findings seen in this trial coupled with the known efficacy of everolimus in patients with SEGA point to the important role of mTOR inhibition with everolimus in treating these manifestations of TSC," said Herve Hoppenot, President, Novartis Oncology. "The outcomes support our further research efforts evaluating everolimus as a treatment option across the various conditions associated with TSC."

Affecting approximately 25,000 to 40,000 people in the US and one to two million people worldwide, TSC is associated with a variety of resulting disorders including skin lesions, seizures, swelling in the brain (hydrocephalus) and developmental delays(3,9).

About EXIST-2 EXIST-2 is a prospective, double-blind, randomized, parallel group, placebo-controlled, international, multicenter Phase III study of everolimus versus placebo for the treatment of patients with angiomyolipoma associated with TSC(1,10). Trial patients (median age=31, range 18-61) were randomized 2:1 to receive either everolimus (n=79) or placebo (n=39) at a daily starting dose of 10 mg. By the cut-off of June 30, 2011, the median treatment duration in the double-blind period was 38.1 weeks (range 2-105 weeks) in the everolimus arm and 3
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... About implantable medical devices Implantable ... augment, or repair damaged tissues or organs. They ... including cosmetic, spinal, cardiovascular, ophthalmic, and neuro-stimulator implantation ... such as polymers, metals, ceramics, and biologics. ... market to grow at a CAGR of 8.54% ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... is an X-linked disease, which generally affects the ... degeneration and weakness. The disease is caused due ... in the lack of production of dystrophin (a ... individuals. The lack of dystrophin weakens muscle function, ...
Breaking Medicine Technology:Global Implantable Medical Devices Market 2015-2019 2Advanced Wound Dressings - SA Analysis and Market Forecasts 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3
... HILL, N.C., Nov. 13 Cempra Pharmaceuticals Inc. today announced ... will present at the Lazard Capital Markets 6th Annual Healthcare ... The St. Regis Hotel in New York City. Dr. ... antibiotic clinical programs for the treatment of drug-resistant pathogens including ...
... China, Nov. 13 Niusule Biotech Corp ... NIUS), a leading U.S.-based biotech company focused on developing ... Mr. Ping (Vince) Huang was named the Company,s chief ... Hu, the Company,s chief executive officer, also served as ...
Cached Medicine Technology:Niusule Announces Key Additions to Management Team 2Niusule Announces Key Additions to Management Team 3
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world ... be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ArtProof ... 17 at the Olympia London, booth #F33 , Be the first to get a ...
(Date:9/3/2015)... ... , ... Hunters Creek Retrievers is again honored to salute America's ... Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 Kisses from a premiere ... Christmas with an extra big smile. , This adorable trained Lab Pup is ...
(Date:9/3/2015)... ... September 03, 2015 , ... A scar is an unavoidable result of incision or ... of the body's ability to heal itself. The appearance of a scar is dependent on ... age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their own over ...
(Date:9/3/2015)... MS (PRWEB) , ... September 03, 2015 , ... ... that their team will be participating at the highly anticipated Mississippi Gulf Babypalooza ... expectant mothers coming from all over, from Gulfport, Biloxi, and beyond. We will ...
(Date:9/3/2015)... Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of ... One in seven men will be diagnosed with prostate cancer during their lifetime. While only ... to six of every 10 men by age 65, according to the American Cancer ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... increase in adult obesity rates in 31 states during the past ... fatal diseases such as// diabetes, stroke and cancer. ... efforts to curb the overweight epidemic, according to a new report ... titled F as in Fat: How Obesity Policies Are Failing America, ...
... Last year about 22,000 operations were cancelled by 34 hospitals ... to the report from these hospitals thousands of patients had ... be admitted to for elective surgery in 2005 had no ... in Dublin had to cancel 4,281 operations last year. Of ...
... shows that California is the fifth worst in the nation ... ,Texas was the worst with an uninsured ... was uninsured. Minnesota had the best record with only 8.7 ... ,New Mexico was noted to have an uninsured rate of ...
... healthcare problem, which has tickled the curiosity of researchers. To ... numbers of myths doing the rounds. To dispel the myths, ... from time to time. , ,A government ... obesity rates by 2010, where one in five girls between ...
... Papworth Hospital, Cambridge, in 1980 for cardiomyopathy died on Sunday ... heart transplant patient having survived for 26 years after undergoing ... diagnosed with cardiomyopathy and had a heart transplant last year. ... muscle becomes inflamed and does not work properly. ...
... specialists declared yesterday that coughing costs the UK economy ... of productivity when sufferers are not well costs approximately ... , ,According to the British Thoracic Society (BTS), ... asthma, drugs or environment factors. ,The BTS ...
Cached Medicine News:Health News:Rise in Obesity Rates in 31 States 2Health News:Rise in Obesity Rates in 31 States 3Health News:Cancellations of Operations touch 22,000 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: